IL6 and congenital rubella syndrome: However, similar to conventional CAR T-cell therapies, CAR-γδT cell approaches face challenges such as cytokine release syndrome (CRS), a potentially severe side effect caused by the massive release of cytokines (e.g., IL-6, TNF-α) from activated T cells or responding immune cells into the bloodstream [246,247].